We find that KDM5 inhibition in luminal breast cancer cells results in R-loop-mediated DNA damage, reduced cell fitness, and an increase in ISG and AP signatures as well as cell surface major histocompatibility complex (MHC) class I, mediated by RNA:DNA hybrid activation of the CGAS/STING pathway. The gene discussed is STING1; the disease is breast carcinoma.